OPKO Health is exploding higher following the announcement on the morning of October 15 that the company reached an agreement to sell select assets of its BioReference Health business to Labcorp Holdings in a deal valued at up to $872 million. This significant divestiture serves as the primary catalyst for the move, overshadowing general positive sentiment regarding the company's Zacks Rank #1 status mentioned in recent industry reports. The stock is currently trading near the upper end of its daily range, reflecting strong investor reaction to the strategic restructuring of its diagnostics operations.